Adma Biologics Surges 2.66% Despite Sector and S&P 500 Gains

Adma Biologics (ADMA) closed at $15.05, up 2.66%, outpacing the S&P 500's 0.34% gain. The stock has dropped 14.77% in the past month, falling short of the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%. Analysts expect an EPS of $0.16, a 6.67% growth, and revenue of $130.1 million, an 8.56% increase. The Zacks Rank system, which takes estimate changes into account, shows Adma Biologics is currently ranked #3 (Hold). The stock's Forward P/E ratio is 25.72, a premium compared to its industry average.

Adma Biologics (ADMA) closed at $15.05 on September 12, 2025, up 2.66% from the previous trading session, outperforming the S&P 500's 0.34% gain. Over the past month, the stock has dropped 14.77%, lagging behind the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54% Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Analysts expect Adma Biologics to post an earnings per share (EPS) of $0.16 for the quarter, representing a 6.67% growth compared to the same period last year. The consensus estimate also projects quarterly revenue of $130.1 million, up 8.56% from the year-ago period Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

The Zacks Rank system, which considers estimate changes, currently ranks Adma Biologics at #3 (Hold). This ranking suggests that while the stock is not a strong buy, it is not a strong sell either. The Zacks Rank has a remarkable track record, with #1 stocks delivering an average annual return of +25% since 1988 Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Adma Biologics' Forward P/E ratio stands at 25.72, indicating a premium compared to its industry average Forward P/E ratio of 19.43. The Medical - Biomedical and Genetics industry, which includes Adma Biologics, has a Zacks Industry Rank of 88, placing it in the top 36% of all 250+ industries Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Investors should closely monitor Adma Biologics' upcoming earnings disclosure, as it could provide further insights into the company's performance and future prospects. Additionally, keeping an eye on the Zacks Rank and valuation metrics can help investors make informed decisions about the stock Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].